Sustainability 1030

Taking responsibility seriously

Angelini Pharma is first and foremostly committed to helping patients. However it acknowledges responsibilities that go much further than this: in line with the formal commitment to stakeholders in its Code of Ethics, the company engages in a wide range of social initiatives throughout Europe and worldwide.

The company is deeply involved in the social field with charitable and fund-raising initiatives, it has organised broad donation programs including blood, medicines and food.
Education is another sector where Angelini Pharma is very active, promoting training for university student and scholarship programs.

An example is the initiative aimed at university students, in Portugal, Turkey and in the Czech Republic, is the Angelini University Awards. This competition encourages students to develop specific healthcare projects. Past winning projects include analytical napkins for patients undergoing palliative treatment, with results presented on a smartphone app; a software platform for improved management of health service resources and a medical device, FixURself, which is connected to a mobile phone app that advises on the best treatment for muscle injuries suffered during sport.

The company is also involved in the sponsorship of associations and foundations that help people facing or being challanged by difficulties.

Angelini Pharma is deeply committed to improving the quality of life of patients, and is sponsoring Headway, an initiative on Brain Health (incl. Mental Health and Epilepsy) conceived and launched in 2017 by the Think Tank The European House - Ambrosetti in partnership with the company, with the aim of creating a multidisciplinary platform for strategic reflection, analysis, dialogue and comparison between various European experiences in the management of individuals with mental and neurological disorders. The initiative keeps the trajectory and works in continuity and coherence with programs, activities and strategies of Governments and International Organizations and scientific societies / patient associations / advocacy groups, as well as of European Institutions, with the objective of contributing to reducing the burden of Mental Health disorders and Epilepsy in Europe. The initiative aims at sharing knowledge and know-how to prevent, diagnose, manage, and find solutions for people with mental disorders and Epilepsy not only in the healthcare sector, but also in workplaces, schools and society in general.

Attention to the environment has never been more important, and Angelini Pharma’s commitment is underlined by the UNI EN ISO 14001:2015 certification of all of its production sites. Important investments have been made in clean energy, with an Energy Management Team that ensures continuous improvements in energy consumption. Recently, a highly advanced energy saving system has been brought into operation in Angelini Pharma's Ancona production plant. This system monitors and exploits favourable conditions in the external atmosphere to reduce the level of cooling of the water used for interiori conditioning. The savings were impressive: electricity consumption was cut by more than 830 MWh with 10,000 m3/per year of drinkable water saved.

The Angelini Pharma Packaging Design structure has been working to reduce the environmental impact of packaging, combining “green” innovation with requirements for product conservation and improvement. The packaging weight and volume have been reduced to optimise transport logistics with consequent reduction in atmospheric pollution from vehicle exhausts. Moreover, recycled materials are extensively used. Today, Angelini Pharma packaging is in line with the strictest international environmental regulations.